www.hczq.com 证券研究报告 | 医药生物 | 2026年2月28日 华创医药投资观点&研究专题周周谈 · 第164期 海外CXO 2025财报总结&2026年展望 本周专题联系人：王宏雨 | 华创医药团队： | | | | --- | --- | --- | | 首席分析师郑辰 | 执业编号：S0360520110002 | 邮箱：zhengchen@hcyjs.com | | 联席首席分析师刘浩 | 执业编号：S0360520120002 | 邮箱：liuhao@hcyjs.com | | 医疗器械组组长李婵娟 | 执业编号：S0360520110004 | 邮箱：lichanjuan@hcyjs.com | | 中药和流通组组长高初蕾 | 执业编号：S0360524070002 | 邮箱：gaochulei@hcyjs.com | | 高级分析师王宏雨 | 执业编号：S0360523080006 | 邮箱：wanghongyu@hcyjs.com | | 高级分析师朱珂琛 | 执业编号：S0360524070007 | 邮箱：zhukechen@hcyjs.com | | 分析师陈俊威 | 执 ...

华创医药投资观点&研究专题周周谈 · 第164期 海外CXO 2025财报总结&2026年展望 www.hczq.com 证券研究报告 | 医药生物 | 2026年2月28日 本周专题联系人：王宏雨 | 华创医药团队： | | | | --- | --- | --- | | 首席分析师郑辰 | 执业编号：S0360520110002 | 邮箱：zhengchen@hcyjs.com | | 联席首席分析师刘浩 | 执业编号：S0360520120002 | 邮箱：liuhao@hcyjs.com | | 医疗器械组组长李婵娟 | 执业编号：S0360520110004 | 邮箱：lichanjuan@hcyjs.com | | 中药和流通组组长高初蕾 | 执业编号：S0360524070002 | 邮箱：gaochulei@hcyjs.com | | 高级分析师王宏雨 | 执业编号：S0360523080006 | 邮箱：wanghongyu@hcyjs.com | | 高级分析师朱珂琛 | 执业编号：S0360524070007 | 邮箱：zhukechen@hcyjs.com | | 分析师陈俊威 | 执 ...

Core Viewpoint - The Hong Kong and A-share markets are experiencing positive trends, with the medical device sector showing signs of recovery, particularly in the context of policy optimization and inventory reduction. MicroTech Medical (02235.HK) has reported significant revenue growth and a return to profitability, driven by strong CGM sales, overseas market expansion, and improved operational efficiency [1][12]. Group 1: Market Trends and Opportunities - The medical device sector is benefiting from favorable market conditions, with a bullish outlook for the industry as a whole [1]. - The global diabetes patient population is projected to exceed 589 million in 2024, with China leading in numbers, indicating a growing market for diabetes management solutions [4]. - Continuous Glucose Monitoring (CGM) technology is transforming blood sugar management, offering real-time data and improving patient experiences compared to traditional methods [5]. Group 2: Company Performance and Growth - MicroTech Medical's revenue for 2025 is expected to reach at least 650 million yuan, representing an approximate 88.1% year-on-year increase, with a net profit of over 38 million yuan [12]. - The company has seen robust growth in its core CGM product, with significant international market expansion contributing to its revenue increase [12]. - The reduction in sales and management expenses has improved profitability, marking a transition from a strategic loss phase to a profit-driven growth stage [12]. Group 3: Strategic Advantages - MicroTech Medical is uniquely positioned with a comprehensive product lineup, including both a patch insulin pump and a real-time CGM, providing a full spectrum solution for diabetes management [16]. - The company is exploring AI applications in CGM, enhancing personalized health management services through data analysis [17]. - The increasing share of overseas revenue demonstrates the company's global market capabilities, with potential for further growth in emerging markets [18]. Group 4: Market Valuation and Future Outlook - The recent performance forecast is expected to catalyze a revaluation of MicroTech Medical's stock, supported by its unique product offerings and global growth potential [20]. - Leading brokerages have expressed optimistic views on the company's future, with target prices indicating significant undervaluation compared to global peers [20].

Industry Overview - The diabetes patient population is expected to reach 853 million globally by 2050, creating significant demand for diagnosis and treatment due to the chronic nature of the disease [3] - The Continuous Glucose Monitoring (CGM) market is projected to grow from $5.7 billion in 2020 to $36.5 billion by 2030, driven by technological advancements [3] - The insulin pump market, particularly patch-style devices, is rapidly developing, with the closed-loop artificial pancreas expected to become mainstream by 2026 [3] Company Profile - Weitai Medical is the only company in China with both a commercially available patch-style insulin pump and a real-time, no-calibration CGM, with the artificial pancreas expected to receive approval by 2026 [4] - The company has established itself as a leader in the domestic market, with superior product performance and a strong distribution network, achieving significant sales milestones such as being the top seller on Tmall for CGM products during the 2025 Double Eleven shopping festival [4] - Weitai Medical's overseas revenue surged to 121 million yuan in the first half of 2025, marking a 218% increase, indicating strong growth potential in international markets [5] Financial Outlook - The company is expected to turn a profit, with operating cash flow turning positive in the first half of 2025, and a projected net profit of 31 million yuan in 2025, increasing to 154 million yuan by 2027 [5] - The current market valuation is significantly undervalued, with a price-to-sales ratio of around 2 times for 2025 revenue, compared to historical valuations of comparable companies [5] - The target market capitalization is set at 5.8 billion HKD, with a target share price of 13.7 HKD, reflecting a strong buy recommendation [5]

Summary of Weitai Medical's Conference Call Company Overview - **Company**: Weitai Medical - **Industry**: Medical Devices, specifically focusing on Continuous Glucose Monitoring Systems (CGMS) and insulin pumps Key Financial Highlights - **Revenue**: In the first half of 2025, Weitai Medical achieved revenue of 270 million CNY, a year-on-year increase of 57.7% [2] - **CGMS Sales**: Sales revenue from CGMS reached 143 million CNY, up 91.5%, accounting for 58.2% of main revenue [2] - **International Market**: International sales contributed 121 million CNY, a staggering 218% increase year-on-year, making up about half of total sales [2][6] - **Loss Reduction**: The company reported a loss of 2.29 million CNY, a significant reduction of 93.9% compared to the previous year [3] - **Cash Reserves**: As of June 30, 2025, the company had cash reserves of 1.716 billion CNY, indicating strong liquidity [3] Product and Market Performance - **Market Coverage**: CGM products are available in over 2,500 hospitals domestically and sold in 118 countries globally [2][6] - **Product Leadership**: The patch insulin pump maintains a leading position in the domestic market [2] - **Regulatory Approvals**: The second-generation CGM has been approved in Europe, with ongoing efforts for reimbursement access in Eastern Europe, Russia, the UK, Italy, and Germany [2][7] - **Future Growth**: The company anticipates growth from CGM products replacing traditional blood glucose meters [2] R&D and Product Development - **Artificial Pancreas Project**: Expected to receive full approval from the National Medical Products Administration by mid-2026, with international approval anticipated by late 2027 [10] - **New Product Pipeline**: The company is developing multiple new products, including a closed-loop insulin pump expected to launch by the end of 2026, and various versions of CGM systems [11][9] - **Clinical Research**: Significant progress in clinical studies for the second-generation CGM targeting pregnant women and other demographics [5] Sales and Marketing Strategy - **Government Subsidies**: National subsidies significantly boosted sales, with over 50% of orders coming from government support [4][12] - **Sales Efficiency**: The sales expense ratio decreased from 66.5% to 37.7%, with expectations to maintain it between 35% and 40% for the year [4][13] - **E-commerce Growth**: Increased sales through e-commerce channels and hospital sales have contributed to overall revenue growth [4][14] Competitive Landscape - **Domestic Competition**: The domestic CGM market is competitive, but Weitai Medical is well-positioned due to its supply chain control and cost management strategies [29] - **International Market Potential**: The international insulin pump market is projected to grow, with Weitai Medical focusing on expanding its presence in Europe and other regions [20] Future Outlook - **Sales Targets**: The company aims for over 100% growth in CGM sales for the year, with confidence in achieving this due to strong domestic and international market performance [13] - **Market Expansion**: Plans to expand into pediatric and adolescent indications for insulin pumps, with expected approvals in 2025 and 2026 [32] - **Long-term Growth**: Continued investment in R&D and innovation is expected to drive future growth, with a focus on maintaining competitive pricing and product quality [33] Additional Insights - **AI Integration**: The company is exploring AI applications in health management and closed-loop treatment systems, although practical applications are still in development [17][18] - **Patent Strategy**: Weitai Medical has a robust patent strategy to mitigate risks and enhance competitiveness in international markets [22][24] This summary encapsulates the key points from Weitai Medical's conference call, highlighting financial performance, product development, market strategies, and future growth prospects.